The Food and Drug Administration recently approved Aurobindo’s generic of Mylan’s Arixtra (fondaparinux sodium) injection. The company has planned January launch for the drug, which is indicated to prevent deep vein thrombosis.
Aurobindo’s generic will be available in single-dose prefilled syringes of 2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml. The product’s market size was $73 million for the 12 months ended October 2017, according to IQVIA data.
January 16, 2018